NCT01852825View on ClinicalTrials.gov

MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 27, 2013

Primary Completion Date

July 20, 2015

Study Completion Date

August 3, 2015

Conditions
Allergic RhinitisAllergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

MK-8237

A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)

OTHER

Placebo

A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)

BIOLOGICAL

NAC

0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84

All Listed Sponsors
collaborator

ALK-Abelló A/S

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01852825 - MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) | Biotech Hunter | Biotech Hunter